Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Issue 12 (12th February 2021)

Record Type:: Journal Article
Title:: Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic. Issue 12 (12th February 2021)
Main Title:: Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
Authors:: McGregor, Colleen GC
Adams, Alex
Sadler, Ross
Arancibia-Cárcamo, Carolina V
Palmer, Rebecca
Ambrose, Tim
Brain, Oliver
Walsh, Alissa
Klenerman, Paul
Travis, Simon PL
Croft, Nicholas M
Lindsay, James O
Satsangi, Jack
Abstract:
Is Part Of:: Gut. Volume 70:Issue 12(2021)
Journal:: Gut
Issue:: Volume 70:Issue 12(2021)
Issue Display:: Volume 70, Issue 12 (2021)
Year:: 2021
Volume:: 70
Issue:: 12
Issue Sort Value:: 2021-0070-0012-0000
Page Start:: 2398
Page End:: 2400
Publication Date:: 2021-02-12
Subjects:: COVID-19 -- infliximab -- inflammatory bowel disease -- paediatric gastroenterology
Gastroenterology -- Periodicals
616.33
Journal URLs:: http://gut.bmjjournals.com ↗
http://www.bmj.com/archive ↗
DOI:: 10.1136/gutjnl-2021-324116 ↗
Languages:: English
ISSNs:: 0017-5749
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 27151.xml